-
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry2020 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Vince B. C. Biemans, Jasmijn A M Sleutjes, Annemarie Charlotte de Vries, Alexander G L Bodelier, Gerard D. H. Dijkstra, Bas Oldenburg, +14 more
88citations -
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases2022 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona D M van Schaik, +15 more
43citations -
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry2022 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Tessa Straatmijer, Fiona D M van Schaik, Alexander G L Bodelier, Marijn Caroline Visschedijk, Annemarie Charlotte de Vries, Cyriel Y. Ponsioen, +13 more
28citations -
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE2023 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Severine A.R.A. Vermeire, Christian Maaser, Silvio Danese, +8 more
22citations -
Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study2024 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Brian G. Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Severine A.R.A. Vermeire, Silvio Danese, +9 more
14citations -
Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease2023 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Joany E. Kreijne, Rogier Goetgebuer, Nicole Stephanie Erler, Nanne K.H. de Boer, Albert G. Siebers, Gerard D. H. Dijkstra, +8 more
13citations -
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply2023 Alimentary Pharmacology & Therapeutics letter Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Mark Löwenberg, Andrea E. van der Meulen‐de Jong, Geert D’Haens
7citations -
The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease2025 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Sebastiaan ten Bokkel Huinink, Michiel T. Bak, Evelien M. J. Beelen, Nicole Stephanie Erler, Mark S. Silverberg, Matthieu Allez, +11 more
5citations -
Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply2020 Alimentary Pharmacology & Therapeutics editorial Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Vera E. R. Asscher, Vince B. C. Biemans, Frank Hoentjen, Jeroen Maljaars
0citations
12 results